The effect of TIPEK(EGF) on the Cultivation of Penaeus Vannamei
1. Objective of the Trial
The purpose of this trial is to add the product "TIPEK(EGF)" to the feed in order to verify its effects in promoting the repair of inTrialinal epithelial damage, growth and development, enhancing the digestive and absorptive capacity of the inTrialine, improving the inTrialinal immune function, comprehensively enhancing the overall health of the animal body, and facilitating growth.
2. Trial Period
Trial Timeline: From September 5, 2024, to October 16, 2024
Duration of Trial: Preparation Phase - 19 days; Formal Trial Phase - 23 days
3. Trial Design
3.1Trial Materials
Trial Animals: 50-day-old Pacific White Shrimp (Litopenaeus vannamei)
The Trial animals should be of pure genetic lineage, with a clear source, healthy, and of uniform size from the same batch. The sex ratio (male to female) should remain consistent across all replicates.
3.2Trial Groups
Table 1
Items
|
Treatments
|
Sample Number
|
Control Group
|
Basal Ration
|
36000×2
|
Trial Group
|
Basal Ration+5kg/t 10% TIPEK(EGF)
|
36000×2
|
3.3 Trial Management 3.3.1 During the trial, feeding and management practices should adhere to the breeding standards of the aquaculture farm. 3.3.2 The water quality conditions across all replicates should remain consistent. 3.3.3 With the exception of routine immunization procedures synchronized with other shrimp populations, maintaining the trial treatment as the sole variable is the principle to follow.
3.4 Sample Collection and Indicator Measurement During the trial, shrimp size was regularly measured and marked weekly. After a 24-hour fasting period following the trial, the shrimp were weighed upon harvest from the pond, with a final marking conducted prior to harvest. Feeding records were maintained throughout the trial period. Upon completion of the growth trial, the total weight of shrimp from each replicate trial was tallied, and indicators such as size, average final weight, and survival rate were calculated. Following the trial, three shrimp from each group were randomly selected, individually measured for body length and weighed, and then dissected to remove the hepatopancreas, which was weighed before being placed in a cryopreservation tube. The hepatopancreas weight, body length, and body weight data were used to calculate indicators such as hepatosomatic index (HSI) and condition factor (K).
Method for Measuring Body Length: A ruler was used to measure the length from the base of the shrimp's eyestalk to the end of its tail segment. Average Final Weight = Marked Weight / Number of Marked Shrimp Survival Rate = Total Weight / Average Final Weight / 36,000 Size = Number of Marked Shrimp / Marked Weight × 500 Hepatosomatic Index (HSI, %) = 100 × Hepatopancreas Weight / Shrimp Body Weight Condition Factor (K) = Body Weight / (Body Length)^3 Additionally, photographs of the shrimp's conditions were taken weekly to maintain a health record.
4. Data Processing and Statistical Analysis
The trial data were initially summarized using Excel. The t-Trial analysis of the results was conducted using SPSS 19.0 statistical software (with P < 0.05 indicating a statistically significant difference). The trial data are presented as "mean ± standard deviation."
5. Result and Anaysis
5.1 Surface observation
5.2 Growth Index
Table 2 Trial Result
|
Control Group
|
Trial Group
|
D-value
|
Incremental percentage
|
Initial Size
|
153.23
|
158.53
|
5.3
|
3.46
|
Final Size
|
89.48
|
89.30
|
-0.18
|
-0.20
|
Growth Size
|
63.75
|
69.23
|
5.48
|
8.60
|
Initial Weight/g
|
3.26
|
3.15
|
-0.11
|
-3.37
|
Final Weight/g
|
5.60
|
5.62
|
0.02
|
0.36
|
Average Weight Gain/g
|
2.34
|
2.47
|
0.13
|
5.56
|
Body Length/cm
|
7.97
|
8.97
|
1
|
12.55
|
Condition Factor
|
4.53
|
6.27
|
1.74
|
38.41
|
Liver-to-Body Ratio%
|
3.75
|
6.17
|
2.42
|
64.53
|
Average Feed Intake per Pond/kg
|
59.55
|
57.63
|
-1.92
|
-3.22
|
FCR
|
0.86
|
0.77
|
-0.09
|
-10.47
|
Survival Rate%
|
82.08
|
84.17
|
2.09
|
2.55
|
As shown in Table 2, the trial group significantly improved the growth performance of the Pacific white shrimp. Specifically, the growth specification of the trial group was 8.6% higher than that of the control group, and the average weight gain was 5.56% higher. Additionally, the body length, condition factor, and hepatosomatic index of the trial group were 12.55%, 38.41%, and 64.53% higher, respectively, compared to the control group. The survival rate of the trial group was also 2.55% higher. Meanwhile, the feed conversion ratio of the trial group was 10.47% lower than that of the control group.
6. Trial Conclusion
The trial group can promote the healthy development of the white shrimp (Litopenaeus vannamei) and significantly improve their growth performance.
|